Skip to main navigation Skip to search Skip to main content

The treatment-naive microbiome in new-onset Crohn's disease

  • Dirk Gevers
  • , Subra Kugathasan
  • , Lee A. Denson
  • , Yoshiki Vázquez-Baeza
  • , Will Van Treuren
  • , Boyu Ren
  • , Emma Schwager
  • , Dan Knights
  • , Se Jin Song
  • , Moran Yassour
  • , Xochitl C. Morgan
  • , Aleksandar D. Kostic
  • , Chengwei Luo
  • , Antonio González
  • , Daniel McDonald
  • , Yael Haberman
  • , Thomas Walters
  • , Susan Baker
  • , Joel Rosh
  • , Michael Stephens
  • Melvin Heyman, James Markowitz, Robert Baldassano, Anne Griffiths, Francisco Sylvester, David Mack, Sandra Kim, Wallace Crandall, Jeffrey Hyams, Curtis Huttenhower, Rob Knight, Ramnik J. Xavier
  • The Broad Institute of MIT and Harvard
  • Emory University
  • Cincinnati Children's Hospital Medical Center
  • University of Colorado Boulder
  • Harvard University
  • University of Minnesota Twin Cities
  • University of Toronto
  • Goryeb Children's Hospital
  • Mayo Clinic Rochester, MN
  • University of California at San Francisco
  • Northwell Health System
  • Children's Hospital of Philadelphia
  • Connecticut Children's Medical Center
  • University of Ottawa
  • Nationwide Children’s Hospital
  • Howard Hughes Medical Institute
  • Massachusetts General Hospital

Research output: Contribution to journalArticlepeer-review

2737 Scopus citations

Abstract

Inflammatory bowel diseases (IBDs), including Crohn's disease (CD), are genetically linked to host pathways that implicate an underlying role for aberrant immune responses to intestinal microbiota. However, patterns of gut microbiome dysbiosis in IBD patients are inconsistent among published studies. Using samples from multiple gastrointestinal locations collected prior to treatment in new-onset cases, we studied the microbiome in the largest pediatric CD cohort to date. An axis defined by an increased abundance in bacteria which include Enterobacteriaceae, Pasteurellacaea, Veillonellaceae, and Fusobacteriaceae, and decreased abundance in Erysipelotrichales, Bacteroidales, and Clostridiales, correlates strongly with disease status. Microbiome comparison between CD patients with and without antibiotic exposure indicates that antibiotic use amplifies the microbial dysbiosis associated with CD. Comparing the microbial signatures between the ileum, the rectum, and fecal samples indicates that at this early stage of disease, assessing the rectal mucosal-associated microbiome offers unique potential for convenient and early diagnosis of CD.

Original languageEnglish
Pages (from-to)382-392
Number of pages11
JournalCell Host and Microbe
Volume15
Issue number3
DOIs
StatePublished - Mar 12 2014

Fingerprint

Dive into the research topics of 'The treatment-naive microbiome in new-onset Crohn's disease'. Together they form a unique fingerprint.

Cite this